Post-Shire-breakup, AbbVie CEO Richard Gonzalez says his company will be scouting about for other "strategic" M&A hookups. But Shire chief Flemming Ornskov isn't interested in courting another buyer.
Valeant partner and leading Allergan shareholder Bill Ackman may have won the right to vote his shares at a Dec. 18 special meeting, at which he hopes to upturn Allergan's board in favor of a slate more friendly to the Canadian pharma's $54 billion hostile bid. But thanks to a judge's opinion, he may soon have some additional insider-trading allegations on his hands.
Indian CRO GVK Biosciences is expanding its capacity in early-phase R&D, buying a local preclinical testing outfit as it works to expand its reach.
Now that Allergan has two interested buyers on its trail between Valeant and Actavis, leading shareholder and Valeant partner Bill Ackman has an idea: Run an auction.
At one time, Allergan was so confident it could lock up an acquisition of Salix Pharmaceuticals to thwart Valeant's hostile bid that it reportedly snubbed potential white knight Actavis when it came calling. But those talks have long since stalled, and now, Salix is investigating an inventory blip that The Wall Street Journal 's sources say was a dealbreaker.
Amid the pharma's slimdown craze, Belgium's UCB is getting in on the action by selling its U.S. generic drug unit for $1.53 billion.
Corporate, or "strategic," investors are busy making digital health investments in smaller companies as they seek to fortify their presence in that important space. So far 2014 boasts about 70 deals worth $800 million, easily exceeding last year's total. Deal volume is nearly double that of 2012.
A $1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $55 billion agreement. But investors? At least one may still be planning a little ax-grinding.
In another sign Siemens is pivoting away from healthcare and towards the energy industry, the German conglomerate announced the sale of its hearing aid business for $2.69 billion to private equity firm EQT Partners and Santo Holding, the investment company of Germany's Strüngmann family.
Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry Valeant. And the business news outlets quickly identified Actavis as the interested party.